Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 492

1.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Jones RL, Ratain MJ, O'Dwyer PJ, Siu LL, Jassem J, Medioni J, DeJonge M, Rudin C, Sawyer M, Khayat D, Awada A, de Vos-Geelen JMPGM, Evans TRJ, Obel J, Brockstein B, DeGreve J, Baurain JF, Maki R, D'Adamo D, Dickson M, Undevia S, Geary D, Janisch L, Bedard PL, Abdul Razak AR, Kristeleit R, Vitfell-Rasmussen J, Walters I, Kaye SB, Schwartz G.

Eur J Cancer. 2019 Sep 12;120:132-139. doi: 10.1016/j.ejca.2019.07.024. [Epub ahead of print]

2.

Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.

Hernandez W, Danahey K, Pei X, Yeo KJ, Leung E, Volchenboum SL, Ratain MJ, Meltzer DO, Stranger BE, Perera MA, O'Donnell PH.

Pharmacogenomics J. 2019 Sep 11. doi: 10.1038/s41397-019-0095-z. [Epub ahead of print]

PMID:
31506565
3.

Assessment of patient knowledge and perceptions of pharmacogenomics before and after using a mock results patient web portal.

Truong TM, Lipschultz E, Danahey K, Schierer E, Ratain MJ, O'Donnell PH.

Clin Transl Sci. 2019 Sep 6. doi: 10.1111/cts.12681. [Epub ahead of print]

PMID:
31490020
4.

The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care.

Truong TM, Apfelbaum J, Shahul S, Anitescu M, Danahey K, Knoebel RW, Liebovitz D, Karrison T, van Wijk XMR, Yeo KJ, Meltzer D, Ratain MJ, O'Donnell PH.

Clin Pharmacol Ther. 2019 Aug 21. doi: 10.1002/cpt.1567. [Epub ahead of print] No abstract available.

PMID:
31433489
5.

Pharmacogenomic considerations for medications in the perioperative setting.

Jhun EH, Apfelbaum JL, Dickerson DM, Shahul S, Knoebel R, Danahey K, Ratain MJ, O'Donnell PH.

Pharmacogenomics. 2019 Jul;20(11):813-827. doi: 10.2217/pgs-2019-0040.

PMID:
31411557
6.

Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.

Levit LA, Peppercorn JM, Tam AL, Marron JM, Mathews DJH, Levit K, Roach N, Ratain MJ.

J Clin Oncol. 2019 Sep 10;37(26):2368-2377. doi: 10.1200/JCO.19.01479. Epub 2019 Jul 25.

PMID:
31343905
7.

Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty.

Ratain MJ.

Clin Pharmacol Ther. 2019 Jul 12. doi: 10.1002/cpt.1546. [Epub ahead of print] No abstract available.

PMID:
31298730
8.

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.

Trendowski MR, El-Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC Jr, Feldman DR, Ardeshir-Rouhani-Fard S, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann F, Einhorn LH, Fossa SD, Travis LB, Dolan ME.

Clin Cancer Res. 2019 Jul 11. doi: 10.1158/1078-0432.CCR-19-0113. [Epub ahead of print]

PMID:
31296530
9.

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.

Ramírez J, House LK, Karrison TG, Janisch LA, Turcich M, Salgia R, Ratain MJ, Sharma MR.

J Clin Pharmacol. 2019 Jul 5. doi: 10.1002/jcph.1476. [Epub ahead of print]

PMID:
31274208
10.

Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment.

Ratain MJ, Goldstein DA, Lichter AS.

JAMA Oncol. 2019 Jun 20. doi: 10.1001/jamaoncol.2019.1341. [Epub ahead of print] No abstract available.

PMID:
31219513
11.

The Role of Early-Phase Design-Letter.

Ratain MJ.

Clin Cancer Res. 2019 May 15;25(10):3190. doi: 10.1158/1078-0432.CCR-19-0350. No abstract available.

PMID:
31092614
12.

Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew.

Strohbehn GW, Ratain MJ.

Clin Pharmacol Ther. 2019 Sep;106(3):498-500. doi: 10.1002/cpt.1428. Epub 2019 Apr 5. No abstract available.

PMID:
30951196
13.

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).

Innocenti F, Jiang C, Sibley AB, Denning S, Etheridge AS, Watson D, Niedzwiecki D, Hatch AJ, Hurwitz HI, Nixon AB, Furukawa Y, Kubo M, Crona DJ, Kindler HL, McLeod HL, Ratain MJ, Owzar K.

Pharmacogenet Genomics. 2019 Aug;29(6):123-131. doi: 10.1097/FPC.0000000000000375.

PMID:
30889042
14.

Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.

Borden BA, Lee SM, Danahey K, Galecki P, Patrick-Miller L, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Kavitt RT, Meltzer DO, Ratain MJ, O'Donnell PH.

Pharmacogenomics J. 2019 Feb 11. doi: 10.1038/s41397-019-0076-2. [Epub ahead of print]

PMID:
30713337
15.

Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.

Lee YM, Danahey K, Knoebel RW, Ratain MJ, Meltzer DO, O'Donnell PH.

Pharmacogenet Genomics. 2019 Feb;29(2):23-30. doi: 10.1097/FPC.0000000000000346.

PMID:
30531378
16.

Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.

Borden BA, Galecki P, Wellmann R, Danahey K, Lee SM, Patrick-Miller L, Sorrentino MJ, Nanda R, Koyner JL, Polonsky TS, Stadler WM, Mulcahy C, Kavitt RT, Ratain MJ, Meltzer DO, O'Donnell PH.

Pharmacogenet Genomics. 2019 Feb;29(2):31-38. doi: 10.1097/FPC.0000000000000362.

PMID:
30531377
17.

The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost.

Ratain MJ.

Clin Cancer Res. 2019 Feb 15;25(4):1136-1138. doi: 10.1158/1078-0432.CCR-18-3513. Epub 2018 Dec 4.

PMID:
30514776
18.

Essential Characteristics of Pharmacogenomics Study Publications.

Thorn CF, Whirl-Carrillo M, Hachad H, Johnson JA, McDonagh EM, Ratain MJ, Relling MV, Scott SA, Altman RB, Klein TE.

Clin Pharmacol Ther. 2019 Jan;105(1):86-91. doi: 10.1002/cpt.1279. Review.

PMID:
30406943
19.

Genetic variation determines VEGF-A plasma levels in cancer patients.

Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K.

Sci Rep. 2018 Nov 5;8(1):16332. doi: 10.1038/s41598-018-34506-4.

20.

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.

Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.

Cancer Med. 2018 Nov;7(11):5478-5487. doi: 10.1002/cam4.1819. Epub 2018 Oct 14.

21.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL.

Clin Pharmacol Ther. 2019 Mar;105(3):738-745. doi: 10.1002/cpt.1241. Epub 2018 Nov 1.

22.

Low-Dose Abiraterone With Food: Rebutting an Editorial.

Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Oct 20;36(30):3060-3061. doi: 10.1200/JCO.2018.79.3018. Epub 2018 Sep 6. No abstract available.

PMID:
30188785
23.

Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

Szmulewitz RZ, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Oct 20;36(30):3064-3065. doi: 10.1200/JCO.2018.79.3190. Epub 2018 Sep 6. No abstract available.

PMID:
30188784
24.

Time Is Money: Optimizing the Scheduling of Nivolumab.

Ratain MJ, Goldstein DA.

J Clin Oncol. 2018 Aug 27:JCO1800045. doi: 10.1200/JCO.18.00045. [Epub ahead of print] No abstract available.

PMID:
30148658
25.

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.

Innocenti F, Owzar K, Jiang C, Etheridge AS, Gordân R, Sibley AB, Mulkey F, Niedzwiecki D, Glubb D, Neel N, Talamonti MS, Bentrem DJ, Seiser E, Yeh JJ, Van Loon K, McLeod H, Ratain MJ, Kindler HL, Venook AP, Nakamura Y, Kubo M, Petersen GM, Bamlet WR, McWilliams RR.

PLoS One. 2018 Aug 14;13(8):e0202272. doi: 10.1371/journal.pone.0202272. eCollection 2018.

26.

Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Hlubocky FJ, Sachs GA, Larson ER, Nimeiri HS, Cella D, Wroblewski KE, Ratain MJ, Peppercorn JM, Daugherty CK.

J Clin Oncol. 2018 Aug 20;36(24):2483-2491. doi: 10.1200/JCO.2017.73.3592. Epub 2018 Jul 9.

27.

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.

Sehdev A, Karrison T, Zha Y, Janisch L, Turcich M, Cohen EEW, Maitland M, Polite BN, Gajewski TF, Salgia R, Pinto N, Bissonnette MB, Fleming GF, Ratain MJ, Sharma MR.

Cancer Chemother Pharmacol. 2018 Aug;82(2):309-317. doi: 10.1007/s00280-018-3619-3. Epub 2018 Jun 9.

28.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

PMID:
29871907
29.

Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

Wellmann R, Borden BA, Danahey K, Nanda R, Polite BN, Stadler WM, Ratain MJ, O'Donnell PH.

Cancer. 2018 Jul 15;124(14):3052-3065. doi: 10.1002/cncr.31382. Epub 2018 May 9.

30.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

31.

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

Maitland ML, Piha-Paul S, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ, Hong D.

Br J Cancer. 2018 Apr;118(8):1042-1050. doi: 10.1038/s41416-018-0020-2. Epub 2018 Mar 19.

32.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Jun 1;36(16):1611-1618. doi: 10.1200/JCO.2017.76.2229. Epub 2018 Feb 13.

33.

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, Yamaguchi R, Wheeler D, Lack J, Cam M, Pontier A, Nguyen YTM, Maejima K, Sasaki-Oku A, Nakano K, Tanaka H, Vander Griend D, Kubo M, Ratain MJ, Miyano S, Nakagawa H.

Eur Urol Focus. 2019 May;5(3):416-424. doi: 10.1016/j.euf.2018.01.006. Epub 2018 Feb 15.

34.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.

Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, Symmans WF, McLeod HL, Ratain MJ, Zembutsu H, Gaedigk A, van Schaik RH, Ingle JN, Caudle KE, Klein TE.

Clin Pharmacol Ther. 2018 May;103(5):770-777. doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

35.

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

Chatelut E, Bruno R, Ratain MJ.

Clin Pharmacol Ther. 2018 Jun;103(6):956-958. doi: 10.1002/cpt.937. Epub 2017 Dec 1.

PMID:
29194586
36.

Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.

House L, Seminerio MJ, Mirkov S, Ramirez J, Skor M, Sachleben JR, Isikbay M, Singhal H, Greene GL, Vander Griend D, Conzen SD, Ratain MJ.

Xenobiotica. 2018 Oct;48(10):973-983. doi: 10.1080/00498254.2017.1386335. Epub 2017 Nov 10.

PMID:
29050522
37.

Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system.

Danahey K, Borden BA, Furner B, Yukman P, Hussain S, Saner D, Volchenboum SL, Ratain MJ, O'Donnell PH.

J Biomed Inform. 2017 Nov;75:110-121. doi: 10.1016/j.jbi.2017.09.012. Epub 2017 Sep 28.

38.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

39.

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ.

Clin Pharmacol Ther. 2017 Nov;102(5):859-869. doi: 10.1002/cpt.709. Epub 2017 Jun 15.

40.

Burdensome Research Procedures in Trials: Why Less Is More.

Kimmelman J, Resnik DB, Peppercorn J, Ratain MJ.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw315.

41.

Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.

Lee YM, McKillip RP, Borden BA, Klammer CE, Ratain MJ, O'Donnell PH.

Pharmacogenet Genomics. 2017 May;27(5):179-189. doi: 10.1097/FPC.0000000000000275.

42.

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ.

Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.

PMID:
28105566
43.

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, Handelman SK, Palmer K, Pulley JM, Beller M, Schildcrout JS, Field JR, Weitzel KW, Cooper-DeHoff RM, Cavallari LH, O'Donnell PH, Altman RB, Pereira N, Ratain MJ, Roden DM, Embi PJ, Sadee W, Klein TE, Johnson JA, Relling MV, Wang L, Weinshilboum RM, Shuldiner AR, Freimuth RR; Pharmacogenomics Research Network Translational Pharmacogenetics Program.

Clin Pharmacol Ther. 2017 Sep;102(3):502-510. doi: 10.1002/cpt.630. Epub 2017 Jun 9.

44.

Food Effect Studies for Oncology Drug Products.

Parsad S, Ratain MJ.

Clin Pharmacol Ther. 2017 May;101(5):606-612. doi: 10.1002/cpt.610. Epub 2017 Mar 20. Review.

PMID:
28073144
45.

Obviating the Need for Serial Biopsies Through Random Assignment.

Sweis RF, Ratain MJ.

J Clin Oncol. 2017 Jan 10;35(2):260. Epub 2016 Oct 31. No abstract available.

PMID:
28056195
46.

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.

McKillip RP, Borden BA, Galecki P, Ham SA, Patrick-Miller L, Hall JP, Hussain S, Danahey K, Siegler M, Sorrentino MJ, Sacro Y, Davis AM, Rubin DT, Lipstreuer K, Polonsky TS, Nanda R, Harper WR, Koyner JL, Burnet DL, Stadler WM, Ratain MJ, Meltzer DO, O'Donnell PH.

Clin Pharmacol Ther. 2017 Jul;102(1):106-114. doi: 10.1002/cpt.586. Epub 2017 Apr 4.

47.

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.

Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M.

Nat Rev Drug Discov. 2017 Jan;16(1):1. doi: 10.1038/nrd.2016.234. Epub 2016 Nov 25. No abstract available.

48.

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

Li M, Seiser EL, Baldwin RM, Ramirez J, Ratain MJ, Innocenti F, Kroetz DL.

Pharmacogenomics J. 2018 Jan;18(1):35-42. doi: 10.1038/tpj.2016.75. Epub 2016 Nov 15.

49.

Drug-Drug Interactions With Oral Antineoplastic Agents.

Parsad S, Ratain MJ.

JAMA Oncol. 2017 Jun 1;3(6):736-738. doi: 10.1001/jamaoncol.2016.3323. No abstract available. Erratum in: JAMA Oncol. 2017 Jun 1;3(6):860.

PMID:
27737450
50.

Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).

de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O'Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D.

Cancer. 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7.

Supplemental Content

Loading ...
Support Center